92 related articles for article (PubMed ID: 27049073)
1. Peripheral blood-derived, γ9δ2 t cell-enriched cell lines from glioblastoma multiforme patients exert anti-tumoral effects in vitro.
Marcu-Malina V; Garelick D; Peshes-Yeloz N; Wohl A; Zach L; Nagar M; Amariglio N; Besser MJ; Cohen ZR; Bank I
J Biol Regul Homeost Agents; 2016; 30(1):17-30. PubMed ID: 27049073
[TBL] [Abstract][Full Text] [Related]
2. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
3. A simple method for the propagation and purification of gamma delta T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2.
Yamaguchi T; Fujimiya Y; Suzuki Y; Katakura R; Ebina T
J Immunol Methods; 1997 Jun; 205(1):19-28. PubMed ID: 9236911
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Mattarollo SR; Kenna T; Nieda M; Nicol AJ
Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.
Crough T; Beagley L; Smith C; Jones L; Walker DG; Khanna R
Immunol Cell Biol; 2012 Oct; 90(9):872-80. PubMed ID: 22508289
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.
Nakazawa T; Nakamura M; Park YS; Motoyama Y; Hironaka Y; Nishimura F; Nakagawa I; Yamada S; Matsuda R; Tamura K; Sugimoto T; Takeshima Y; Marutani A; Tsujimura T; Ouji N; Ouji Y; Yoshikawa M; Nakase H
J Neurooncol; 2014 Jan; 116(1):31-9. PubMed ID: 24062140
[TBL] [Abstract][Full Text] [Related]
7. γ9δ2T cell diversity and the receptor interface with tumor cells.
Vyborova A; Beringer DX; Fasci D; Karaiskaki F; van Diest E; Kramer L; de Haas A; Sanders J; Janssen A; Straetemans T; Olive D; Leusen J; Boutin L; Nedellec S; Schwartz SL; Wester MJ; Lidke KA; Scotet E; Lidke DS; Heck AJ; Sebestyen Z; Kuball J
J Clin Invest; 2020 Sep; 130(9):4637-4651. PubMed ID: 32484803
[TBL] [Abstract][Full Text] [Related]
8. Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations.
Nerdal PT; Peters C; Oberg HH; Zlatev H; Lettau M; Quabius ES; Sousa S; Gonnermann D; Auriola S; Olive D; Määttä J; Janssen O; Kabelitz D
J Immunol; 2016 Oct; 197(8):3059-3068. PubMed ID: 27619996
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.
Bryant NL; Gillespie GY; Lopez RD; Markert JM; Cloud GA; Langford CP; Arnouk H; Su Y; Haines HL; Suarez-Cuervo C; Lamb LS
J Neurooncol; 2011 Jan; 101(2):179-88. PubMed ID: 20532954
[TBL] [Abstract][Full Text] [Related]
11. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
12. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.
Jin J; Joo KM; Lee SJ; Jo MY; Kim Y; Jin Y; Kim JK; Ahn JM; Yoon MJ; Lim J; Nam DH
Oncol Rep; 2011 Jan; 25(1):33-9. PubMed ID: 21109954
[TBL] [Abstract][Full Text] [Related]
13. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.
Bryant NL; Suarez-Cuervo C; Gillespie GY; Markert JM; Nabors LB; Meleth S; Lopez RD; Lamb LS
Neuro Oncol; 2009 Aug; 11(4):357-67. PubMed ID: 19211933
[TBL] [Abstract][Full Text] [Related]
14. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
16. Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Thomas AA; Fisher JL; Hampton TH; Christensen BC; Tsongalis GJ; Rahme GJ; Whipple CA; Steel SE; Davis MC; Gaur AB; Lewis LD; Ernstoff MS; Fadul CE
Cancer Immunol Immunother; 2017 Mar; 66(3):379-389. PubMed ID: 27942839
[TBL] [Abstract][Full Text] [Related]
17. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.
Greenfield JP; Jin DK; Young LM; Christos PJ; Abrey L; Rafii S; Gutin PH
Neurosurgery; 2009 May; 64(5):819-26; discussion 826-7. PubMed ID: 19404145
[TBL] [Abstract][Full Text] [Related]
18. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme.
Fisher T; Galanti G; Lavie G; Jacob-Hirsch J; Kventsel I; Zeligson S; Winkler R; Simon AJ; Amariglio N; Rechavi G; Toren A
Cancer J; 2007; 13(5):335-44. PubMed ID: 17921733
[TBL] [Abstract][Full Text] [Related]
20. Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme.
Lee M; Park C; Woo J; Kim J; Kho I; Nam DH; Park WY; Kim YS; Kong DS; Lee HW; Kim TJ
Front Immunol; 2019; 10():555. PubMed ID: 30967876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
